Dimethylamine

Dimethylamine

SCHEMBL7033752

CNC.Cc1cc(CC(C)C)cc(CC(C)C)c1O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.50
GABRA1 P14867 2/20 0.49
GABRB2 P47870 2/20 0.49
HMGB1 P09429 1/20 0.36
CXCL12 P48061 1/20 0.36
NR3C1 P04150 1/20 0.35
PGR P06401 1/20 0.35
NR3C2 P08235 1/20 0.35
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
BCL2 P10415 1/20 0.32
MCL1 Q07820 1/20 0.32
LDHA P00338 1/20 0.31
LDHB P07195 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23387416 0.94 GABRA1 (0.53) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL38650833 0.94 GABRA1 (0.53) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL8186747 0.82 CA1 (0.46) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL1538588 0.82 GABRA1 (0.61) GABRA1GABRB2NR3C1PGRESR1
SCHEMBL11679976 0.79 ALOX15 (0.50) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL16501712 0.78 SHBG (0.42) SHBGGABRA1GABRB2PTGS1PTGS2
SCHEMBL26113500 0.78 GABRA1 (0.39) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL16182676 0.78 SHBG (0.50) SHBGGABRA1GABRB2HMGB1CXCL12
SCHEMBL5588281 0.77 GABRA1 (0.60) GABRA1GABRB2NR3C1PGRESR1
SCHEMBL6934299 0.77 GABRA1 (0.47) SHBGGABRA1GABRB2NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5011857-A Administering 2,4-di-isobutyl-6-(n,n-dimethylaminomethyl)-phenol; antiinflammatory agent, alleviating psoriasis, diabetes, atheroschlerosis MERRELL DOW PHARMACEUTICALS INC. (US) 1991-04-30 US claimed
EP-0284879-A2 Method of inhibiting interleukin-1 release MERRELL DOW PHARMACEUTICALS INC. (US) 1988-10-05 EP claimed
US-20030092684-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders ANTIBODY SYSTEMS, INC. 2003-05-15 US disclosed
US-20020077276-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders ANTIBODY SYSTEMS, INC. 2002-06-20 US disclosed
EP-1171163-A1 COMPOSITIONS CONTAINING TETRACYCLINES FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS Antibody Systems, Inc. (US) 2002-01-16 EP disclosed
WO-2000064479-A1 COMPOSITIONS CONTAINING TETRACYCLINES FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS ANTIBODY SYSTEMS, INC. (US) 2000-11-02 WO disclosed
EP-0627438-B1 METHANEDIPHOSPHONATE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF TORAY INDUSTRIES (JP) 1999-01-13 EP disclosed
US-5565440-A ANTIINFLAMMATORY, ANTIPYRITIC, ANALGESIC, ANTIRHEUMATIC, ANTIARTHRITIC OR ANTIOSTEOPROSIS AGENT TORAY INDUSTRIES, INC. (JP) 1996-10-15 US disclosed
US-5034412-A Antiinflammatory agents, skin disorders, antidiabetic agents or antiatherosclerosis agents MERRELL DOW PHARMACUETICALS INC. (US) 1991-07-23 US disclosed
US-5011857-A Administering 2,4-di-isobutyl-6-(n,n-dimethylaminomethyl)-phenol; antiinflammatory agent, alleviating psoriasis, diabetes, atheroschlerosis MERRELL DOW PHARMACEUTICALS INC. (US) 1991-04-30 US disclosed
EP-0284879-A3 METHOD OF INHIBITING INTERLEUKIN-1 RELEASE MERRELL DOW PHARMACEUTICALS INC. (US) 1990-10-17 EP disclosed
US-4870101-A TETRAETHYLTHIURAM DISULFIDE MERRELL DOW PHARMACEUTICALS INC. (US) 1989-09-26 US disclosed
EP-0284879-A2 Method of inhibiting interleukin-1 release MERRELL DOW PHARMACEUTICALS INC. (US) 1988-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020077276-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders IL1R1, TNF, IL1A SHBG 651/4885GABRA1 2759/4885GABRB2 4149/4885
US-20030092684-A1 Compositions and methods for treating hemorrhagic virus infections and other disorders CCL11, SSB, TNF SHBG 702/4885GABRA1 4695/4885GABRB2 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.